Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph 1/2 LOXO-292 Solid Tumors, Including RET Fusion-Pos Solid Tumors, Thyroid Ca,& Tumors w/LIBRETTO

Protocol: OSU-17109

Full Title

A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)